1 Year Absolute Returns
-
NAV (₹) on 16 Nov 2026
10.57
1 Day NAV Change
0.28%
Risk Level
Very High Risk
Rating
-
Invesco India Pharma and Healthcare Fund is a Equity mutual fund categorized under Sector, offered by Invesco Asset Management (India) Private Limited. Launched on 18 Aug 2026, investors can start ... Read more
AUM
₹ 475.83 Cr
| Sectors | Weightage |
|---|---|
| Hospitals & Medical Services | 47.50% |
| Pharmaceuticals | 42.23% |
| Medical Equipment & Accessories | 7.31% |
| Treps/Reverse Repo | 3.16% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 9.08% | ₹ 43.21 | Hospitals & Medical Services |
| Divi's Laboratories Limited | 8.74% | ₹ 41.57 | Pharmaceuticals |
| Max Healthcare Institute Limited | 8.59% | ₹ 40.89 | Hospitals & Medical Services |
| Sai Life Sciences Limited | 8.49% | ₹ 40.41 | Pharmaceuticals |
| Sun Pharmaceutical Industries Limited | 8.31% | ₹ 39.54 | Pharmaceuticals |
| Manipal Health Enterprises Ltd | 7.97% | ₹ 37.94 | Hospitals & Medical Services |
| Dr Agarwals Health Care Limited | 7.93% | ₹ 37.73 | Hospitals & Medical Services |
| Sahajanand Medical Technologies Limited | 7.31% | ₹ 34.80 | Medical Equipment & Accessories |
| Global Health Limited | 5.96% | ₹ 28.36 | Hospitals & Medical Services |
| Corona Remedies Limited | 5.76% | ₹ 27.42 | Pharmaceuticals |
| Glenmark Pharmaceuticals Limited | 4.48% | ₹ 21.33 | Pharmaceuticals |
| Torrent Pharmaceuticals Limited | 4.42% | ₹ 21.03 | Pharmaceuticals |
| Krishna Institute Of Medical Sciences Limited | 4.38% | ₹ 20.83 | Hospitals & Medical Services |
| Aster DM Quality Care Limited | 3.59% | ₹ 17.10 | Hospitals & Medical Services |
| Triparty Repo | 3.16% | ₹ 15.02 | Others |
| Mankind Pharma Limited | 2.03% | ₹ 9.67 | Pharmaceuticals |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | - | - | - | - |
| Category returns | 7.37% | 5.10% | 9.83% | 22.69% |
To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance ... Read more
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Pharma and Healthcare Fund - Direct Plan
Sector
Direct
|
₹23.46 | 30.32% | 124.36% | 0.00% | ₹3,666 | 1.03% |
Very High
|
What is the current NAV of Invesco India Pharma and Healthcare Fund Regular IDCW-Reinvestment?
What is the fund size (AUM) of Invesco India Pharma and Healthcare Fund Regular IDCW-Reinvestment?
What are the historical returns of Invesco India Pharma and Healthcare Fund Regular IDCW-Reinvestment?
What is the risk level of Invesco India Pharma and Healthcare Fund Regular IDCW-Reinvestment?
What is the minimum investment amount for Invesco India Pharma and Healthcare Fund Regular IDCW-Reinvestment?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article